{
  "purpose": "mechanism illustration and published summary recalculation; no individual risk/threshold model",
  "decay_reference": 0.125,
  "decay_scenarios": [
    {
      "label": "基准起点，半衰期35天",
      "initial": 1.0,
      "half_life_days": 35.0,
      "reference_crossing_day": 105.0
    },
    {
      "label": "起点提高4倍，半衰期35天",
      "initial": 4.0,
      "half_life_days": 35.0,
      "reference_crossing_day": 175.0
    },
    {
      "label": "相同起点，半衰期70天",
      "initial": 1.0,
      "half_life_days": 70.0,
      "reference_crossing_day": 210.0
    }
  ],
  "extra_days_from_fourfold_start": 70.0,
  "matisse_final_descriptive_endpoints": [
    {
      "endpoint": "RSV相关严重就医LRTI",
      "through_days": 90,
      "VE": 82.4,
      "lo95": 57.5,
      "hi95": 93.9
    },
    {
      "endpoint": "RSV相关严重就医LRTI",
      "through_days": 180,
      "VE": 70.0,
      "lo95": 50.6,
      "hi95": 82.5
    },
    {
      "endpoint": "RSV相关就医LRTI",
      "through_days": 90,
      "VE": 57.6,
      "lo95": 31.3,
      "hi95": 74.6
    },
    {
      "endpoint": "RSV相关住院",
      "through_days": 90,
      "VE": 69.7,
      "lo95": 37.1,
      "hi95": 86.7
    },
    {
      "endpoint": "RSV相关住院",
      "through_days": 180,
      "VE": 55.3,
      "lo95": 23.8,
      "hi95": 74.6
    },
    {
      "endpoint": "所有病因就医LRTI",
      "through_days": 90,
      "VE": 4.1,
      "lo95": -9.5,
      "hi95": 16.0
    }
  ],
  "melody_protocol_definition": [
    {
      "season": 1,
      "group": "首季nirsevimab组",
      "cases": 24,
      "denominator": 2009,
      "percent": 1.1946241911398707,
      "lo95": 0.8040912508589482,
      "hi95": 1.7714448696593346
    },
    {
      "season": 2,
      "group": "首季nirsevimab组",
      "cases": 19,
      "denominator": 1944,
      "percent": 0.977366255144033,
      "lo95": 0.6265921487687123,
      "hi95": 1.5215015079925889
    },
    {
      "season": 1,
      "group": "首季安慰剂组",
      "cases": 54,
      "denominator": 1003,
      "percent": 5.383848454636091,
      "lo95": 4.149612154493052,
      "hi95": 6.958537777244281
    },
    {
      "season": 2,
      "group": "首季安慰剂组",
      "cases": 10,
      "denominator": 967,
      "percent": 1.0341261633919339,
      "lo95": 0.5626737214976785,
      "hi95": 1.8930783072274804
    }
  ],
  "second_season_crude_RR": 0.9451131687242799,
  "second_season_approximate_RR_CI95": [
    0.44119121449643217,
    2.024607182433531
  ],
  "limitations": [
    "Decay parameters are self-selected illustrations, not a fitted newborn or dosing model.",
    "VE values and CIs are reported final-analysis estimates, not re-estimated from patient-level data.",
    "MELODY crude proportions/intervals ignore unequal follow-up beyond the published denominator; no noninferiority claim."
  ]
}